Information Provided By:
Fly News Breaks for August 12, 2016
PTI
Aug 12, 2016 | 07:47 EDT
Leerink analyst Joseph Schwartz raised his price target for Proteostasis to $20 from $15 after the company reported promising data from a Phase 1 study of its PTI-248, which is being developed as an add-on to amplify the effect of currently approved therapies for cystic fibrosis. Leerink has an Outperform rating on the shares.
News For PTI From the Last 2 Days
There are no results for your query PTI